// Biotech and Pharma Therapeutics
Smiths Medical recalls infusion pumps over 3 problems
June 4, 2025 / Infusion pump recall / CADD-Solis pump issues / Smiths Medical safety alert / FDA Class I recall / Medical device malfunction
Smiths Medical recalled certain CADD-Solis infusion pumps due to risks of false alarms, thermal damage, and intermittent wireless connections—each capable of interrupting treatment. While no injuries were reported, the FDA classifies these issues as posing serious risk to patient safety.
CDC official overseeing COVID-19 vaccine recommendations resigns
June 4, 2025 / CDC resignation / COVID-19 vaccine guidance / Lakshmi Panagiotakopoulos resigns / HHS vaccine directive / CDC leadership change
Dr. Lakshmi Panagiotakopoulos has resigned from her role overseeing COVID-19 vaccine guidance at the CDC, citing inability to continue protecting vulnerable populations following directive changes imposed by Health and Human Services Secretary Robert F. Kennedy Jr.
5 Defining Moments from Some of the Top 100 Medical Device Companies
June 3, 2025 / Top medtech companies / Medical device innovation / Medtech industry trends / MD+DI Top 100 / Medical technology leadership
MD+DI highlights five pivotal moments from its annual Top 100 Medical Device Companies list, showcasing innovations and decisions that have significantly shaped the medtech landscape, influencing patient care, regulatory strategy, and global market leadership in medical technology.
The Top 5 Home Care Franchise Opportunities in the U.S.
June 4, 2025 / Home care franchises / Senior care services / Nonmedical caregiving business / Aging population healthcare / In-home elder support
As aging populations increase demand for in-home care, top U.S. home care franchises like HomeWell, Visiting Angels, and Home Instead offer scalable, compassionate services that support senior independence while addressing chronic disease management, post-hospital recovery, and dementia care needs.
5 attributes every AI system will soon need to make hay in healthcare
June 3, 2025 / Explainable AI / Federated learning healthcare / Medical data integration / AI in diagnostics / Personalized medicine AI
AI in healthcare will increasingly require explainability, causal inference, federated learning, multimodal data integration, and continuous adaptation to ensure accuracy, transparency, and trust—paving the way for collaborative, personalized, and ethically sound medical care alongside human clinicians.
// 4th Industrial Revolution
Cognixion, Pupil Labs partner on eye-tracking interface
June 4, 2025 / Explainable AI / Federated learning healthcare / Medical data integration / AI in diagnostics / Personalized medicine AI
AI in healthcare will increasingly require explainability, causal inference, federated learning, multimodal data integration, and continuous adaptation to ensure accuracy, transparency, and trust—paving the way for collaborative, personalized, and ethically sound medical care alongside human clinicians.
AI and clinicians compared in handling complex medical cases
June 4, 2025 / AI in healthcare / Clinical decision support / Medical empathy AI / Healthcare workforce shortage / Ethical AI integration
A University of Maine study found AI tools matched clinical standards in factual cases but lacked consistency and empathy in complex medical scenarios, emphasizing the need for human oversight, ethical design, and culturally adaptive integration in healthcare settings.
How Agentic AI Simplifies Healthcare Workflows and Reduces Administrative Overhead
June 4, 2025 / Healthcare AI / Workflow automation / Administrative burden reduction / AI in clinical operations / Unstructured data processing
Agentic AI streamlines healthcare workflows by processing unstructured data, automating administrative tasks like prior authorizations and case management. This reduces physician burden, accelerates care delivery, and improves outcomes—shifting time and focus from paperwork to patient care.
Balancing AI Innovation with Rising Cyber Threats in Healthcare
June 4, 2025 / Healthcare cybersecurity / AI in healthcare / Deepfake medical fraud / Data poisoning risks / AI governance
As AI transforms healthcare operations and diagnostics, it also introduces major cyber vulnerabilities—from deepfake fraud to data poisoning. Balancing innovation with robust cybersecurity is essential to protect patient safety, data integrity, and healthcare system resilience.
AI spots future breast cancer risk in mammograms years before diagnosis
June 3, 2025 / AI breast cancer screening / Mammogram risk prediction / Early breast cancer detection / Personalized cancer screening / Artificial intelligence in radiology
A large cohort study shows that AI can identify subtle mammographic features predictive of breast cancer up to six years before diagnosis, offering a powerful tool for personalized risk assessment and earlier, more targeted screening strategies.
// Business & Markets
Highridge Medical Completes Sale of Bone Healing Unit to Avista
June 4, 2025 / Bone healing therapy / Spinal device innovation / Highridge Medical divestiture / Avista Healthcare acquisition / Non-invasive bone stimulation
Highridge Medical has sold its Bone Healing division to Avista to focus solely on spine care. The move supports Highridge’s strategy to invest in spinal innovation, while the divested unit will continue developing bone growth stimulation therapies independently.
CVS Health commits $20B to health-tech initiatives
June 4, 2025 / CVS Health investment / Healthcare interoperability / Patient-centered care / Health-tech innovation / Digital health transformation
CVS Health plans to invest $20B over 10 years to enhance tech-enabled care, improve interoperability across providers, and streamline the patient experience—aiming for unified records, automated workflows, and proactive care across its vertically integrated healthcare ecosystem.
Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs
June 4, 2025 / GLP-1 obesity drugs / Long-acting incretin therapies / Eli Lilly Camurus deal / Mounjaro Zepbound innovation / Extended-release metabolic treatments
Eli Lilly partnered with Camurus in a deal worth up to $870M to develop long-acting GLP-1–based obesity and diabetes drugs, aiming to extend dosing intervals and maintain leadership in the competitive incretin-based metabolic therapy market.
LEO Pharma strengthens strategic leadership
June 4, 2025 / LEO Pharma leadership / Medical dermatology strategy / Helle Hedegaard Juhl / Pharma HR transformation / Global pharmaceutical leadership
LEO Pharma has appointed Helle Hedegaard Juhl as EVP of Global People and Corporate Affairs to strengthen its leadership team and support its organizational transformation in advancing innovation and global strategy within medical dermatology.
J&J may take a softer tariff hit after US-China pause, CFO says
June 4, 2025 / Johnson & Johnson tariffs / Medtech supply chain / US-China trade pause / J&J earnings forecast / Medical device manufacturing
Johnson & Johnson may reduce its estimated $400M tariff impact to $200M following a temporary U.S.-China trade pause, primarily benefiting its medtech division. J&J maintains strong EPS growth projections and a dual-source manufacturing strategy to navigate global tariff uncertainties.
// Legal & Regulatory
Bayer gains key FDA expansion for fast-rising prostate cancer drug Nubeqa
June 4, 2025 / Nubeqa FDA approval / metastatic prostate cancer treatment / androgen receptor inhibitor / Bayer oncology pipeline / prostate cancer clinical trial
Bayer’s Nubeqa received FDA approval for use with ADT in all metastatic castration-sensitive prostate cancer patients, including those intolerant to chemo. The ARANOTE Phase 3 trial showed a 46% reduction in disease progression or death compared to ADT alone.
MHRA guidance on development and use of phage therapies
June 4, 2025 / phage therapy guidance / antibiotic resistance treatment / MHRA phage regulation / personalized bacterial therapy / UK phage medicine
The UK’s MHRA has issued its first official guidance to support the safe development of phage therapies, aiming to standardize production for both broad-use and personalized treatments targeting antibiotic-resistant bacterial infections when conventional antibiotics fail.
Freenome posts pivotal liquid biopsy data as FDA filing nears completion
June 4, 2025 / liquid biopsy cancer / Freenome colorectal screening / blood-based cancer detection / early cancer diagnosis / JAMA colorectal trial
Freenome’s pivotal trial data in JAMA show its blood-based colorectal cancer test met primary endpoints with 79.2% sensitivity and 91.5% specificity, but underperformed in detecting precancerous lesions—key for early intervention—compared to stool-based alternatives like Cologuard Plus.
Roche’s Evrysdi tablet approved by EC for SMA
June 4, 2025 / Evrysdi tablet approval / SMA treatment Europe / Roche risdiplam update / non-invasive SMA therapy / spinal muscular atrophy drug
The European Commission approved Roche’s new tablet formulation of Evrysdi (risdiplam) for spinal muscular atrophy (SMA), offering a room-temperature stable, non-invasive treatment option that enhances convenience and flexibility for home administration without compromising efficacy or safety.
Takeda wins new EC approval for Adcetris
June 4, 2025 / Adcetris EC approval / Hodgkin lymphoma treatment / Takeda brentuximab vedotin / ECADD chemotherapy regimen / Stage III Hodgkin lymphoma
The European Commission approved Takeda’s Adcetris (brentuximab vedotin) in combination with ECADD chemotherapy for adults with newly diagnosed Stage IIb with risk factors, III, or IV Hodgkin lymphoma, expanding frontline treatment options for advanced-stage disease.
// Research & Development
Neuralink competitor Paradromics completes first human implant
June 3, 2025 / brain-computer interface / Paradromics implant trial / neural signal recording / epilepsy neurosurgery BCI / Connexus BCI system
Paradromics has completed its first human implant of a brain-computer interface (BCI), demonstrating safe neural signal recording. The procedure supports future trials aimed at helping patients with severe motor impairments communicate through computer systems.
Alto re-arms in depression after failure
June 4, 2025 / treatment resistant depression / dopamine agonist therapy / ALTO-207 acquisition / pramipexole ondansetron combo / neuropsychiatric drug development
Alto Neuroscience is acquiring a portfolio of dopamine agonist drug combinations, including ALTO-207, to target treatment-resistant depression. ALTO-207 combines pramipexole and ondansetron to enhance antidepressant efficacy while minimizing side effects.
Vigil’s rare brain disease drug flunks phase 2 study, but Sanofi takeover is unaffected
June 4, 2025 / TREM2 agonist failure / iluzanebart phase 2 results / Sanofi Vigil acquisition / ALSP treatment trial / Amgen drug rights
Vigil Neuroscience’s TREM2 agonist, iluzanebart, failed to meet efficacy and biomarker endpoints in a phase 2 trial for ALSP. Despite this, Sanofi’s $470M acquisition of Vigil proceeds, excluding rights to iluzanebart, which revert to Amgen.
Bayer drug could ease side effects of common breast cancer treatment, detailed data show
June 3, 2025 / Elinzanetant breast cancer / non-hormonal menopause treatment / vasomotor symptom relief / endocrine therapy side effects / Bayer Oasis-4 trial
Bayer’s non-hormonal drug elinzanetant significantly reduced vasomotor symptoms like hot flashes and sleep disruption in women on endocrine therapy for hormone receptor-positive breast cancer, offering a safer symptom management alternative without compromising cancer outcomes.
BioAge deepens weight loss R&D with fresh apelin receptor push
June 4, 2025 / BioAge obesity pipeline / apelin receptor agonist / JiKang Therapeutics nanobody / weight loss drug development / liver-safe obesity treatment
BioAge Labs is advancing its obesity pipeline by partnering with JiKang Therapeutics on a novel apelin receptor nanobody and developing proprietary agonists, aiming to overcome prior liver toxicity issues with a new drug application targeted for 2026.
// Politics
10.9 million people would lose health insurance under Trump’s tax cut bill, CBO projects
June 4, 2025 / Trump tax bill healthcare / CBO health insurance loss / ACA subsidy cuts / uninsured Americans projection / healthcare policy impact
The CBO projects that nearly 11 million people would lose health insurance under the proposed Trump tax bill, with a total of 16 million potentially affected over a decade due to expiring ACA subsidies and new regulatory changes.
mRNA, once lauded as a scientific marvel, is now a government target
June 2, 2025 / mRNA vaccine funding / Moderna H5N1 flu / pandemic preparedness setback / mRNA technology politics / mRNA cancer vaccine potential
Federal cuts to mRNA vaccine funding—totaling over $700 million—signal a politicized shift away from a proven technology critical for pandemic preparedness and potential cancer therapies, raising alarm among biotech leaders and public health experts.
US regulator to review abortion drug after political pressure
June 4, 2025 / mifepristone safety review / FDA abortion pill evaluation / Josh Hawley mifepristone pressure / medical abortion drug risks / mifepristone adverse event data
The FDA will review mifepristone’s safety following political pressure, particularly from Senator Josh Hawley, citing concerns over adverse events. The review will analyze post-marketing data but no immediate regulatory changes have been promised.
Drugmakers beg Trump administration to rethink pharma tariffs
May 30, 2025 / pharmaceutical import tariffs / drug supply chain risk / generic drug access / pharma industry response / medication cost increase
Pharmaceutical companies are urging the Trump administration to reconsider proposed drug import tariffs, warning they could destabilize supply chains, increase drug prices, and limit access—especially for generics sourced from China and India, which comprise over 90% of U.S. prescriptions.
EU tests industry and patients’ patience with delayed pharma law
June 3, 2025 / pharma reform delay / drug shortages / EU legislation / patient access
The EU’s long-delayed pharma legislation risks worsening drug access and investment flight. Prolonged negotiations over data protection, generics, and regulatory timelines may undermine innovation and patient care while global competitors like the U.S. attract pharmaceutical capital.